Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.

Before 2011, 17α-hydroxyprogesterone caproate (17P) was used to prevent recurrent preterm birth in women with singleton pregnancies and was compounded at a low cost (∼$15 per injection). In 2011, the U.S.